Abbott Sells In Vitro, Point-Of-Care Diagnostics Businesses To General Electric For $8 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal continues Abbott’s strategy over the last few years of becoming more focused on its pharmaceuticals business.